Abstract
The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Current Vascular Pharmacology
Title: Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Volume: 6 Issue: 1
Author(s): Rudiger J. Seitz and Mario Siebler
Affiliation:
Keywords: Stroke, fibrinolysis, reperfusion, hemorrhage, receptor polymorphism
Abstract: The goal of acute stroke therapy is to salvage brain tissue by rapid cerebral artery recanalization to improve microcirculation. A major drawback of fibrinolysis is the activation of platelets leading to a high rate of re-occlusion. Antagonists of the platelet GPIIb/IIIa-receptor inhibit the binding of fibrinogen to platelets counteracting secondary thrombus formation. Also, they were shown to suppress thrombembolus formation and to limit lesion development in cerebral ischemia. We review the literature concerning the use of intravenously administered GPIIb/IIIa-receptor antagonists abciximab, eptifibatide and tirofiban for the treatment of patients with acute ischemic brain infarction. In multicenter, prospective, randomized and placebo-controlled trials abciximab had a higher cerebral bleeding risk, while tirofiban did not increase hemorrhage. When combined with fibrinolysis, abciximab and tirofiban were found to improve cerebral artery recanalization and tissue reperfusion resulting in reduced infarct volumes and improved neurological outcome. Thus, GPIIb/IIIareceptor antagonists have a great potential for the treatment of acute stroke.
Export Options
About this article
Cite this article as:
Seitz J. Rudiger and Siebler Mario, Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease, Current Vascular Pharmacology 2008; 6 (1) . https://dx.doi.org/10.2174/157016108783331303
DOI https://dx.doi.org/10.2174/157016108783331303 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines
Current Drug Targets New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Melatonin and Male Reproductive Health: Relevance of Darkness and Antioxidant Properties
Current Molecular Medicine Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Cytomegalovirus Infections in Non-Immunocompromised and Immunocompromised Patients in the Intensive Care Unit
Infectious Disorders - Drug Targets Markers of Early Vascular Ageing
Current Pharmaceutical Design Changes in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirnas Regulating their Expression Under the Adalimumab Therapy
Current Pharmaceutical Biotechnology Interview: Dr. Muin J. Khoury Discusses the Future of Public Health Genomics and why it Matters for Personalized Medicine and Global Health
Current Pharmacogenomics and Personalized Medicine Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Functional Genomics Approaches in Cancer Research
Current Genomics Monitoring and Surveillance of Obesity in the United States
Current Nutrition & Food Science GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design In Vivo Models of Childhood Leukemia for Preclinical Drug Testing
Current Drug Targets Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Interventional Radiology in Paediatrics
Current Pediatric Reviews NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets